<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Anaesthesiol Intensive Care</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Anaesthesiol Intensive Care</journal-id><journal-id journal-id-type="pmc-domain-id">4677</journal-id><journal-id journal-id-type="pmc-domain">ejaic</journal-id><journal-id journal-id-type="publisher-id">EJAIC</journal-id><journal-title-group><journal-title>European Journal of Anaesthesiology and Intensive Care</journal-title></journal-title-group><issn pub-type="epub">2767-7206</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11783651</article-id><article-id pub-id-type="pmcid-ver">PMC11783651.1</article-id><article-id pub-id-type="pmcaid">11783651</article-id><article-id pub-id-type="pmcaiid">11783651</article-id><article-id pub-id-type="pmid">39917370</article-id><article-id pub-id-type="doi">10.1097/EA9.0000000000000007</article-id><article-id pub-id-type="publisher-id">EJAIC-D-22-00025</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The influence of haemorrhagic shock on the pharmacokinetic and pharmacodynamic effects of remimazolam in a swine model</article-title><subtitle>A laboratory study</subtitle></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kurita</surname><given-names initials="T">Tadayoshi</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kawashima</surname><given-names initials="S">Shingo</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Khaleelullah</surname><given-names initials="MMSI">Mohamed Mathar Sahib Ibrahim</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Morita</surname><given-names initials="K">Koji</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kurosawa</surname><given-names initials="Y">Yuko</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Naito</surname><given-names initials="T">Takafumi</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nakajima</surname><given-names initials="Y">Yoshiki</given-names></name></contrib></contrib-group><aff>From the Department of Anesthesiology and Intensive Care (T-K, S-K, MMSI-K, K-M, Y-N), Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu, Japan (Y-K, T-N)</aff><author-notes><corresp>Correspondence to Tadayoshi Kurita, Department of Anesthesiology and Intensive Care, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu 431-3192, Japan. Tel: +81 53 435 2738; fax: +81 53 434 1812; e-mail: <email>tadkur@hama-med.ac.jp.</email></corresp></author-notes><pub-date pub-type="collection"><month>8</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>19</day><month>9</month><year>2022</year></pub-date><volume>1</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">480943</issue-id><fpage>e007</fpage><lpage>e007</lpage><pub-history><event event-type="pmc-release"><date><day>19</day><month>09</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>06</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-07 15:25:21.147"><day>07</day><month>02</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Society of Anaesthesiology and Intensive Care.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0</ext-link>
</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ejaic-1-e007.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ejaic-1-e007.pdf"/><abstract><sec sec-type="background"><title>BACKGROUND</title><p>Haemorrhagic shock enhances the potency of several intravenous anaesthetics.</p></sec><sec><title>OBJECTIVE</title><p>To assess the influence of haemorrhagic shock on the pharmacokinetic and pharmacodynamic effects of remimazolam, a new short-acting benzodiazepine.</p></sec><sec><title>DESIGN</title><p>An animal observational study.</p></sec><sec><title>SETTING</title><p>An animal laboratory in Hamamatsu University School of Medicine, Hamamatsu, Japan, from 3 April to 7 June 2021.</p></sec><sec><title>ANIMALS</title><p>Ten pigs, 24.5&#8202;&#177;&#8202;0.5 (mean&#8202;&#177;&#8202;standard deviation) kg.</p></sec><sec><title>INTERVENTIONS</title><p>Pigs were anaesthetised with isoflurane, and raw electroencephalographic waveforms, bispectral index (BIS) and 95% spectral edge frequency (SEF) were recorded throughout the study. After isoflurane was stopped, remimazolam was administered at a rate of 150&#8202;mg&#8202;h<sup>&#8722;1</sup> for 10&#8202;min and arterial blood was collected 16 times until 180&#8202;min to measure the remimazolam concentration (baseline condition). After the baseline measurements, haemorrhagic shock was induced by 750&#8202;ml bleeding and maintained for 40&#8202;min. The same dose of remimazolam was administered again (4&#8202;h after the first remimazolam infusion) and blood samples were collected.</p></sec><sec><title>MAIN OUTCOME MEASURES</title><p>Pharmacokinetic variables were quantified using a three-compartment model and the pharmacodynamic variables were estimated using an inhibitory sigmoid maximal effect model.</p></sec><sec sec-type="results"><title>RESULTS</title><p>The peak remimazolam concentration increased from 1.0&#8202;&#177;&#8202;0.3 to 1.5&#8202;&#177;&#8202;0.4&#8202;&#956;g&#8202;ml<sup>&#8722;1</sup>. Haemorrhagic shock decreased the central compartment volume, elimination clearance, and fast distribution clearance by 30 to 50%. The effect-site concentration producing 50% of the maximal BIS effect was 0.10&#8202;&#177;&#8202;0.09&#8202;&#956;g&#8202;ml<sup>&#8722;1</sup> at baseline and 0.11&#8202;&#177;&#8202;0.09&#8202;&#956;g&#8202;ml<sup>&#8722;1</sup> during haemorrhagic shock (<italic toggle="yes">P</italic>&#8202;=&#8202;0.78), and that of SEF was 0.09&#8202;&#177;&#8202;0.03 and 0.11&#8202;&#177;&#8202;0.04&#8202;&#956;g&#8202;ml<sup>&#8722;1</sup>, respectively (<italic toggle="yes">P</italic>&#8202;=&#8202;0.28).</p></sec><sec sec-type="conclusion"><title>CONCLUSION</title><p>Haemorrhagic shock alters the pharmacokinetics of remimazolam, but does not enhance the end-organ sensitivity. Because the impact of haemorrhagic shock is small, remimazolam might be a suitable sedative/hypnotic for the management of patients who have massive bleeding.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>
<boxed-text position="float" orientation="portrait"><sec><title>KEY POINTS</title><list list-type="bullet"><list-item><p>The influence of haemorrhagic shock on the pharmacokinetic and pharmacodynamic effects of remimazolam, a new ultra-short acting benzodiazepine, is unclear.</p></list-item><list-item><p>Haemorrhagic shock alters the pharmacokinetics of remimazolam by increasing the peak concentration and duration of EEG effects 1.5-fold, but does not change the end-organ sensitivity.</p></list-item><list-item><p>The impact of haemorrhagic shock on the hypnotic effect of remimazolam is limited; therefore, remimazolam might be a more suitable sedative/hypnotic than propofol for the management of patients who have significant blood loss.</p></list-item></list></sec></boxed-text></p><sec sec-type="intro"><title>Introduction</title><p>Haemorrhagic shock enhances the potency of several intravenous anaesthetics.<sup><xref rid="R1" ref-type="bibr">1</xref>&#8211;<xref rid="R6" ref-type="bibr">6</xref></sup> It also increases drug concentrations when associated with a decrease in the distribution volume and clearance, which further increases the end-organ sensitivity of some intravenous anaesthetics.<sup><xref rid="R1" ref-type="bibr">1</xref>&#8211;<xref rid="R6" ref-type="bibr">6</xref></sup> These pharmacokinetic and pharmacodynamic changes require a reduction in the administered dose depending on the individual intravenous anaesthetic used,<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup> complicating the appropriate anaesthetic management of patients who have significant blood loss before and during surgery.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup> In this regard, propofol is a poor choice.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup> Animal haemorrhagic shock studies have demonstrated the potentiated hypotensive effect of propofol,<sup><xref rid="R4" ref-type="bibr">4</xref></sup> and that plasma concentrations and end-organ sensitivity were increased 2.5-fold and 2.7-fold, respectively, compared with normal conditions.<sup><xref rid="R6" ref-type="bibr">6</xref></sup> Fluid resuscitation reversed these pharmacokinetic changes, but the increased end-organ sensitivity remained<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup> because of the increased amount of unbound propofol.<sup><xref rid="R10" ref-type="bibr">10</xref></sup></p><p>Remimazolam, an ultra-short-acting benzodiazepine, is a new sedative/hypnotic used for the induction and maintenance of general anaesthesia in Japan.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> Remimazolam is rapidly metabolised by liver carboxylesterase to an inactive metabolite,<sup><xref rid="R12" ref-type="bibr">12</xref></sup> and is therefore superior to midazolam, which can prolong recovery from sedation because of its active metabolite (&#945;-hydroxymidazolam).<sup><xref rid="R12" ref-type="bibr">12</xref></sup> Therefore, during haemorrhagic shock, the effect of midazolam can be prolonged because of the alterations to the pharmacokinetics of midazolam and &#945;-hydroxymidazolam.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> Remimazolam induces minimum cardiovascular depression and can thus be safely used for the induction and maintenance of anaesthesia in patients who are haemodynamically unstable<sup><xref rid="R14" ref-type="bibr">14</xref>&#8211;<xref rid="R16" ref-type="bibr">16</xref></sup> and at high risk of complications, such as those with American Society of Anesthesiologists physical status III.<sup><xref rid="R17" ref-type="bibr">17</xref></sup></p><p>On the basis of these pharmacological advantages, remimazolam might be a useful sedative/hypnotic for patients suffering from haemorrhagic shock in emergency and ICUs, and also those expecting to develop massive haemorrhage during surgery. At present, no studies have reported how haemorrhagic shock might alter the effects of remimazolam.</p><p>We conducted this study in swine to examine the influence of haemorrhagic shock on the pharmacokinetic and pharmacodynamic effects of remimazolam. We hypothesised that haemorrhagic shock increased the remimazolam concentration, related to pharmacokinetic changes, but did not change the end-organ sensitivity.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Ethics</title><p>Ethical approval for this study (approval number 2020071) was provided by the Ethics Committee of the Animal Research Division at Hamamatsu University School of Medicine, Hamamatsu, Japan on 4 March 2021.</p></sec><sec><title>Animal preparation</title><p>All the experiments in this study were conducted on 10 swine in accordance with the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines. The pigs comprised two males and eight females, body weight (mean&#8202;&#177;&#8202;SD) 24.5&#8202;&#177;&#8202;0.5&#8202;kg, range 23.8 to 25.5&#8202;kg and approximately 2&#8202;months old. All animals were sheltered with unrestricted water and food before experiments. General anaesthesia was induced by the inhalation of 5% isoflurane and oxygen using an animal face mask, and a tracheostomy was performed. Anaesthesia was maintained with 2.5% isoflurane (approximately 1.2 minimum alveolar anaesthetic concentration<sup><xref rid="R18" ref-type="bibr">18</xref></sup>) with an oxygen-air mixture (fraction of inspiratory oxygen&#8202;=&#8202;0.6) through mechanical ventilators. An IntelliVue G5-M1019A (Philips Medical Systems, Eindhoven, the Netherlands) was used to analyse the exhaled gases. The end-tidal carbon dioxide partial pressure was confirmed as 35 to 45&#8202;mmHg during the animal preparation period, and the ventilator setting was maintained throughout the experiment. Three cutaneous electrodes were used to monitor electrocardiographic lead II. A 14-gauge double-lumen catheter and 5-F pulmonary artery catheter (Nihon Kohden, Tokyo, Japan) were inserted via the right jugular vein, and 16-gauge catheters were inserted into the bilateral femoral arteries for the continuous measurement of arterial blood pressure and collecting blood samples. All processes from tracheostomy to catheter insertions were performed under local anaesthetic or general anaesthesia. An isotonic saline solution was infused at 100 ml h<sup>&#8722;1</sup> for maintenance. An electric heater and air conditioning were used to maintain the body temperature at 37.0&#176;C to 38.5&#176;C throughout the study. At the end of the animal preparations, electroencephalogram (EEG) monitoring was initiated using an Aspect A-1000 instrument with software version 3.0 (Aspect Medical Systems, Natick, Massachusetts, USA) using five cutaneous needle electrodes placed on the bilateral frontal and occipital regions, with the centre of the frontal region as the ground. Low-pass and high-pass filters were set at 0.2 and 70&#8202;Hz, respectively. Raw EEG waveform, bispectral index (BIS) and spectral edge frequency (SEF) values were collected electronically at two second intervals until the end of the experiment.</p></sec><sec><title>Experimental protocol</title><p>After the animal preparation was completed, the inhalation of isoflurane was terminated. After confirming that the end-tidal isoflurane (Fig. <xref rid="F1" ref-type="fig">1</xref>) concentration had decreased to less than 0.2% and EEG variables had returned to awake conditions, remimazolam was infused at a rate of 150&#8202;mg&#8202;h<sup>&#8722;1</sup> for 10&#8202;min (total of 25&#8202;mg to a 25&#8202;kg pig) via the right jugular vein (baseline condition). The remimazolam dose (1&#8202;mg&#8202;kg<sup>&#8722;1</sup>) was based on our pilot studies, in which induction of sleep in the pigs was confirmed. Isoflurane was washed out before remimazolam infusion because isoflurane masks the effect of remimazolam on EEG making the pharmacodynamic analysis difficult. Arterial blood samples (2&#8202;ml) were collected at 4, 8, 10, 11, 12, 13, 14, 15, 17.5, 20, 25, 30, 40, 60, 120 and 180&#8202;min after the start of remimazolam infusion. The inhalation of isoflurane was restarted at 120&#8202;min to induce sleep in the animals. After blood sampling at 180&#8202;min, arterial blood was withdrawn to a mean arterial pressure (MAP) of 50&#8202;mmHg and removed or re-infused to maintain a MAP of 50&#8202;mmHg for 20&#8202;min (isobaric haemorrhagic model). Maximal blood loss amount was set to 750&#8202;ml (approximate 43% of the estimated circulatory volume in a 25&#8202;kg pig) to avoid animal death. Then, haemorrhagic shock was maintained for 40&#8202;min, and the inhalation of isoflurane was terminated at 20&#8202;min (halfway through the maintenance of haemorrhagic shock). After confirming that the end-tidal isoflurane concentration had decreased to less than 0.2% and EEG variables had returned to the awake condition, remimazolam was infused again (240&#8202;min after the first remimazolam infusion) at a rate of 150&#8202;mg&#8202;h<sup>&#8722;1</sup> for 10&#8202;min and arterial blood samples were collected at 4, 8, 10, 11, 12, 13, 14, 15, 17.5, 20, 25, 30, 40, 60, 120 and 180&#8202;min after the start of remimazolam infusion similar to that for the baseline condition. The inhalation of isoflurane was restarted after the sampling at 120&#8202;min. Heart rate (HR), MAP, mean pulmonary arterial pressure (MPA), central venous pressure (CVP) and cardiac output (CO) at baseline and after haemorrhagic shock were recorded just before and after remimazolam infusion and metabolic variables were measured just before remimazolam infusion.</p><fig position="float" id="F1" orientation="portrait"><label>Fig. 1</label><caption><p>Time course of the experiment. Time zero indicates the start of the 150&#8202;mg&#8202;h<sup>&#8722;1</sup> remimazolam infusion at baseline. Remimazolam was infused again at 240&#8202;min during haemorrhagic shock.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ejaic-1-e007-g001.jpg"/></fig></sec><sec><title>Remimazolam assay</title><p>Arterial blood samples were immediately centrifuged, and plasma was stored at &#8722;80&#176;C until sample pretreatment. The detailed methods of sample pretreatment were reported previously.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> A certain volume of D4-remimazolam was added as internal standard to each plasma sample and used for internal standard calibration to measure the remimazolam concentration precisely. Remimazolam plasma concentrations were measured by liquid chromatography tandem mass spectrometry (LC-MS/MS) with a lower limit of detection of 0.4&#8202;ng&#8202;ml<sup>&#8722;1</sup> and a linear range of 0.4 to 4500&#8202;ng&#8202;ml<sup>&#8722;1</sup>. The intra- and inter-assay accuracies and coefficients of variation were 96.5 and 1.3%, and 97.2 and 0.8%, respectively. Detailed explanations of chromatographic and mass spectrometric conditions were reported previously.<sup><xref rid="R19" ref-type="bibr">19</xref></sup></p></sec><sec><title>Pharmacokinetic analysis</title><p>The pharmacokinetics of remimazolam were quantified using a three-compartment model using concentration versus time data, as described previously in our propofol study,<sup><xref rid="R20" ref-type="bibr">20</xref></sup> and the pharmacokinetic variables for each animal were calculated. The remimazolam concentration in the central compartment (C<sub>1</sub>) was determined using the differential equation dC<sub>1</sub>/dt&#8202;=&#8202;&#8722; (k<sub>12</sub>&#8202;+&#8202;k<sub>13</sub>&#8202;+&#8202;k<sub>10</sub>)&#8202;C<sub>1</sub>&#8202;+&#8202;k<sub>21</sub>&#8202;C<sub>2</sub>&#8202;V<sub>2</sub>/V<sub>1</sub>&#8202;+&#8202;k<sub>31</sub>&#8202;C<sub>3</sub>&#8202;V<sub>3</sub>/V<sub>1</sub>&#8202;+&#8202;R, in which C<sub>2</sub> and V<sub>2</sub> are the concentration and distribution volume in the rapid peripheral compartment, C<sub>3</sub> and V<sub>3</sub> are those in the slow peripheral compartment, k<sub>ij</sub> is the rate constant for transfer from the i-compartment to the j-compartment, k<sub>10</sub> is the elimination constant from the central compartment to outside the body and R is the infusion rate during remimazolam infusion. These pharmacokinetic variables were fitted to the measured remimazolam concentration versus time data by least-squares regression using the Solver tool in Microsoft Excel (Microsoft Excel 2019; Microsoft Corporation, Redmond, Washington, USA).</p></sec><sec><title>Pharmacodynamic analysis</title><p>We previously reported the influence of haemorrhagic shock,<sup><xref rid="R20" ref-type="bibr">20</xref>&#8211;<xref rid="R22" ref-type="bibr">22</xref></sup> &#946;-blockers,<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup> endotoxaemia<sup><xref rid="R25" ref-type="bibr">25</xref></sup> and intracranial space occupying lesions<sup><xref rid="R26" ref-type="bibr">26</xref></sup> on the EEG effect of isoflurane or propofol, which was characterised by examining its effect on the BIS or SEF. The same pharmacodynamic analysis was used in the present study. The BIS and SEF were related to the effect-site concentration (Ce) derived from the first-order decay of the remimazolam concentration (Cp): dCe/dt&#8202;=&#8202;k<sub>e0</sub> (Cp &#8722; Ce), where k<sub>e0</sub> is the elimination constant from the effect site, which determines the equilibration between Cp and Ce. The k<sub>e0</sub> value was calculated for each animal using nonlinear least-squares fitting, and the optimisation of k<sub>e0</sub> was accomplished using the Solver tool in Microsoft Excel by minimising the area bounded by the hysteresis loop plotted between the BIS or SEF values every 2&#8202;min and the Cp values at the respective times. The following inhibitory sigmoid E<sub>max</sub> equation (Hill equation<sup><xref rid="R27" ref-type="bibr">27</xref></sup>) was used to model the relationship parametrically for an individual animal. E&#8202;=&#8202;E<sub>0</sub> &#8722; (E<sub>0</sub> &#8722; E<sub>max</sub>) X [Ce<sup>&#947;</sup>/(Ce<sup>&#947;</sup>&#8202;+&#8202;EC<sub>50</sub><sup>&#947;</sup>)], in which E is the predicted effect, E<sub>0</sub> is the baseline effect, E<sub>max</sub> is the maximal effect, EC<sub>50</sub> is the effect-site concentration that produces 50% of the maximal effect and &#947; is a measure of the curve steepness. The values in the model were estimated using nonlinear least square fitting in Microsoft Excel, through optimisation with the Solver tool to minimise the sum of squares between the estimated and measured BIS and SEF values. The coefficient of determination (<italic toggle="yes">R</italic><sup>2</sup>) was calculated as described previously.<sup><xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref></sup></p></sec><sec><title>Statistical analysis</title><p>Data are shown as mean&#8202;&#177;&#8202;SD. Haemodynamic and metabolic variables, and pharmacokinetic and pharmacodynamic variables for each state were analysed using paired <italic toggle="yes">t</italic>-tests. <italic toggle="yes">P</italic> values less than 0.05 were considered statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><p>The total blood volume withdrawn reached 750&#8202;ml (maximum volume) in all pigs after maintenance of the isobaric haemorrhagic model (MAP&#8202;=&#8202;50&#8202;mmHg) for 20&#8202;min. One pig died after 750&#8202;ml of bleeding and before remimazolam infusion, leaving nine pigs for analysis. Haemorrhagic shock increased the HR and lactate level (<italic toggle="yes">P</italic>&#8202;&lt;&#8202;0.0001 and 0.0009), and decreased the MAP, CVP, CO, <italic toggle="yes">P</italic>a<sc>CO</sc><sub>2</sub> and base excess (<italic toggle="yes">P</italic>&#8202;=&#8202;0.0020, 0.0044, &lt;0.0001, &lt;0.0001 and 0.0002, respectively) (Table <xref rid="T1" ref-type="table">1</xref>). Remimazolam infusion decreased the MAP in both conditions (<italic toggle="yes">P</italic>&#8202;=&#8202;0.0002 and 0.0163) and the HR and MPA during haemorrhagic shock (<italic toggle="yes">P</italic>&#8202;=&#8202;0.0404 and 0.0140).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Haemodynamic variables before and immediately after remimazolam infusion, and metabolic variables before remimazolam infusion in each state.</p></caption><table frame="hsides" rules="groups" border="0"><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Baseline</th><th align="center" colspan="2" rowspan="1">Haemorrhagic shock</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Before infusion</th><th align="center" rowspan="1" colspan="1">After infusion</th><th align="center" rowspan="1" colspan="1">Before infusion</th><th align="center" rowspan="1" colspan="1">After infusion</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HR (beats&#8202;min<sup>&#8722;1</sup>)</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">166&#8202;&#177;&#8202;34</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">143&#8202;&#177;&#8202;28</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">239&#8202;&#177;&#8202;26<sup>&#8727;</sup></td><td align="char" char="&#xB1;" rowspan="1" colspan="1">217&#8202;&#177;&#8202;36<sup>&#8727;&#8727;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">MAP (mmHg)</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">99&#8202;&#177;&#8202;18</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">78&#8202;&#177;&#8202;14<sup>&#8727;&#8727;</sup></td><td align="char" char="&#xB1;" rowspan="1" colspan="1">72&#8202;&#177;&#8202;14<sup>&#8727;</sup></td><td align="char" char="&#xB1;" rowspan="1" colspan="1">60&#8202;&#177;&#8202;13<sup>&#8727;&#8727;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">MPA (mmHg)</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">18&#8202;&#177;&#8202;3</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">17&#8202;&#177;&#8202;2</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">17&#8202;&#177;&#8202;2</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">15&#8202;&#177;&#8202;2<sup>&#8727;&#8727;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">CVP (mmHg)</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">2&#8202;&#177;&#8202;2</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">2&#8202;&#177;&#8202;2</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">&#8722;1&#8202;&#177;&#8202;1<sup>&#8727;</sup></td><td align="char" char="&#xB1;" rowspan="1" colspan="1">&#8722;1&#8202;&#177;&#8202;2</td></tr><tr><td align="left" rowspan="1" colspan="1">CO (l min<sup>&#8722;1</sup>)</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">3.1&#8202;&#177;&#8202;0.5</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">3.0&#8202;&#177;&#8202;0.5</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">2.0&#8202;&#177;&#8202;0.5<sup>&#8727;</sup></td><td align="char" char="&#xB1;" rowspan="1" colspan="1">2.0&#8202;&#177;&#8202;0.5</td></tr><tr><td align="left" rowspan="1" colspan="1">pH</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">7.49&#8202;&#177;&#8202;0.03</td><td rowspan="1" colspan="1"/><td align="char" char="&#xB1;" rowspan="1" colspan="1">7.46&#8202;&#177;&#8202;0.04</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic>a<sc>CO</sc><sub>2</sub> (mmHg)</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">37.4&#8202;&#177;&#8202;4.4</td><td rowspan="1" colspan="1"/><td align="char" char="&#xB1;" rowspan="1" colspan="1">32.4&#8202;&#177;&#8202;4.7<sup>&#8727;</sup></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic>a<sc>O</sc><sub>2</sub> (mmHg)</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">174&#8202;&#177;&#8202;46</td><td rowspan="1" colspan="1"/><td align="char" char="&#xB1;" rowspan="1" colspan="1">167&#8202;&#177;&#8202;40</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Base excess (mmol&#8202;l<sup>-1</sup>)</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">5.0&#8202;&#177;&#8202;1.1</td><td rowspan="1" colspan="1"/><td align="char" char="&#xB1;" rowspan="1" colspan="1">-0.3&#8202;&#177;&#8202;3.3<sup>&#8727;</sup></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Lactate (mmol&#8202;l<sup>-1</sup>)</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">2.1&#8202;&#177;&#8202;0.6</td><td rowspan="1" colspan="1"/><td align="char" char="&#xB1;" rowspan="1" colspan="1">4.4&#8202;&#177;&#8202;1.8<sup>&#8727;</sup></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Haematocrit (%)</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">30.1&#8202;&#177;&#8202;2.9</td><td rowspan="1" colspan="1"/><td align="char" char="&#xB1;" rowspan="1" colspan="1">28.9&#8202;&#177;&#8202;2.4</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Data are expressed as mean&#8202;&#177;&#8202;SD.</p><p>CO, cardiac output; CVP, central venous pressure; HR, heart rate; MAP, mean arterial blood pressure; MPA, mean pulmonary arterial pressure.</p></fn><fn id="T1fn1"><label>&#8727;</label><p><italic toggle="yes">P</italic>&#8202;&lt;&#8202;0.05 versus before remimazolam infusion in baseline condition.</p></fn><fn id="T1fn2"><label>&#8727;&#8727;</label><p><italic toggle="yes">P</italic>&#8202;&lt;&#8202;0.05 versus before remimazolam infusion in each state.</p></fn></table-wrap-foot></table-wrap><p>
Figure <xref rid="F2" ref-type="fig">2</xref> shows the changes in the mean remimazolam concentrations in each condition. At all sampling timepoints, remimazolam concentrations during haemorrhagic shock were significantly higher than those at baseline, and the peak concentration (10&#8202;min) increased from 1.0&#8202;&#177;&#8202;0.3 to 1.5&#8202;&#177;&#8202;0.4&#8202;&#956;g&#8202;ml<sup>&#8722;1</sup> (<italic toggle="yes">P</italic>&#8202;=&#8202;0.0001). Pharmacokinetic analysis (Table <xref rid="T2" ref-type="table">2</xref>) demonstrated that haemorrhagic shock decreased the distribution volume of the central compartment (<italic toggle="yes">P</italic>&#8202;=&#8202;0.0010), elimination clearance (<italic toggle="yes">P</italic>&#8202;&lt;&#8202;0.0001) and fast distribution clearance (<italic toggle="yes">P</italic>&#8202;=&#8202;0.0123), compared with baseline. The distribution volume of the rapid peripheral compartment (<italic toggle="yes">P</italic>&#8202;=&#8202;0.3182), slow peripheral compartment (<italic toggle="yes">P</italic>&#8202;=&#8202;0.4854) and slow distribution clearance (<italic toggle="yes">P</italic>&#8202;=&#8202;0.9704), did not change after haemorrhage occurred.</p><fig position="float" id="F2" orientation="portrait"><label>Fig. 2</label><caption><p>Mean remimazolam concentration versus time during and after 150&#8202;mg&#8202;h<sup>&#8722;1</sup> of remimazolam for 10&#8202;min. Solid circles&#8202;=&#8202;mean plasma concentration during baseline condition. Open circles&#8202;=&#8202;mean plasma concentration during haemorrhagic shock. At each sampling timepoint, the remimazolam concentration during haemorrhagic shock was significantly higher than that at baseline.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ejaic-1-e007-g002.jpg"/></fig><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Pharmacokinetic variables in each state.</p></caption><table frame="hsides" rules="groups" border="0"><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">Haemorrhagic shock</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Central compartment: V<sub>1</sub> (ml&#8202;kg<sup>&#8722;1</sup>)</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">99&#8202;&#177;&#8202;36</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">69&#8202;&#177;&#8202;20</td><td align="char" char="." rowspan="1" colspan="1">0.0010</td></tr><tr><td align="left" rowspan="1" colspan="1">Rapid peripheral compartment: V<sub>2</sub> (ml&#8202;kg<sup>&#8722;1</sup>)</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">395&#8202;&#177;&#8202;280</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">304&#8202;&#177;&#8202;258</td><td align="char" char="." rowspan="1" colspan="1">0.3182</td></tr><tr><td align="left" rowspan="1" colspan="1">Slow peripheral compartment: V<sub>3</sub> (ml&#8202;kg<sup>&#8722;1</sup>)</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">684&#8202;&#177;&#8202;548</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">882&#8202;&#177;&#8202;507</td><td align="char" char="." rowspan="1" colspan="1">0.4854</td></tr><tr><td align="left" rowspan="1" colspan="1">Elimination clearance: Cl<sub>1</sub> (ml&#8202;kg<sup>&#8722;1</sup>&#8202;min<sup>&#8722;1</sup>)</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">64&#8202;&#177;&#8202;18</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">40&#8202;&#177;&#8202;15</td><td align="char" char="." rowspan="1" colspan="1">&lt; 0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Fast distribution clearance: Cl<sub>2</sub> (ml&#8202;kg<sup>&#8722;1</sup>&#8202;min<sup>&#8722;1</sup>)</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">58&#8202;&#177;&#8202;33</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">28&#8202;&#177;&#8202;16</td><td align="char" char="." rowspan="1" colspan="1">0.0123</td></tr><tr><td align="left" rowspan="1" colspan="1">Slow distribution clearance: Cl<sub>3</sub> (ml&#8202;kg<sup>&#8722;1</sup>&#8202;min<sup>&#8722;1</sup>)</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">18&#8202;&#177;&#8202;12</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">18&#8202;&#177;&#8202;13</td><td align="char" char="." rowspan="1" colspan="1">0.9704</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Data are expressed as mean&#8202;&#177;&#8202;SD.</p></fn></table-wrap-foot></table-wrap><p>Individual BIS and SEF responses during and after remimazolam infusion are shown in Fig. <xref rid="F3" ref-type="fig">3</xref>. The peak depression of BIS and SEF at 10&#8202;min after the start of remimazolam infusion did not differ between baseline and haemorrhagic shock (BIS; 72&#8202;&#177;&#8202;6 <italic toggle="yes">versus</italic> 74&#8202;&#177;&#8202;8, and SEF; 15.6&#8202;&#177;&#8202;1.2 <italic toggle="yes">versus</italic> 16.0&#8202;&#177;&#8202;1.3, respectively) (<italic toggle="yes">P</italic>&#8202;=&#8202;0.30 and 0.52), but the times to return to pre-infusion EEG values during haemorrhagic shock were longer than those at baseline (BIS; 102.9&#8202;&#177;&#8202;31.3 <italic toggle="yes">versus</italic> 68.9&#8202;&#177;&#8202;15.6&#8202;min and SEF; 77.9&#8202;&#177;&#8202;28.4 <italic toggle="yes">versus</italic> 56.6&#8202;&#177;&#8202;16.8&#8202;min, respectively) (<italic toggle="yes">P</italic>&#8202;=&#8202;0.0157 and 0.029). Individual relationships between the effect-site concentration and predicted effect, and a summary of the pharmacodynamic variables are shown in Fig. <xref rid="F4" ref-type="fig">4</xref> and Table <xref rid="T3" ref-type="table">3</xref>. The effect-site concentration producing 50% of the maximal BIS effect was 0.10&#8202;&#177;&#8202;0.09&#8202;&#956;g&#8202;ml<sup>&#8722;1</sup> at baseline and 0.11&#8202;&#177;&#8202;0.09&#8202;&#956;g&#8202;ml<sup>&#8722;1</sup> during haemorrhagic shock; <italic toggle="yes">P</italic>&#8202;=&#8202;0.7761, mean difference 0.015; 95% CI for the difference &#8722;0.086 to 0.116, and the effect-site concentration producing 50% of the maximal SEF effect was 0.09&#8202;&#177;&#8202;0.03&#8202;&#956;g&#8202;ml<sup>&#8722;1</sup> at baseline and 0.11&#8202;&#177;&#8202;0.04&#8202;&#956;g&#8202;ml<sup>&#8722;1</sup> during haemorrhagic shock (<italic toggle="yes">P</italic>&#8202;=&#8202;0.2807, mean difference 0.016; 95% CI for the difference &#8722;0.011 to 0.042). The EC<sub>50</sub> values were similar for the BIS and SEF, and haemorrhagic shock did not alter the EC<sub>50</sub> value of either EEG index.</p><fig position="float" id="F3" orientation="portrait"><label>Fig. 3</label><caption><p>Individual bispectral index and 95% spectral edge frequency changes versus time profiles at baseline and during haemorrhagic shock. The bold line in each figure represents the mean change.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ejaic-1-e007-g003.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>Fig. 4</label><caption><p>Individual relationships between the predicted bispectral index or 95% spectral edge frequency and effect-site remimazolam concentration (Ce) at baseline and during haemorrhagic shock. The bold line in each figure represents the mean change.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ejaic-1-e007-g004.jpg"/></fig><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Pharmacodynamic variables in each state.</p></caption><table frame="hsides" rules="groups" border="0"><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">Haemorrhagic shock</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">Bispectral index (BIS)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;k<sub>e0</sub> (min<sup>&#8722;1</sup>)</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">0.53&#8202;&#177;&#8202;0.17</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">0.84&#8202;&#177;&#8202;0.71</td><td align="char" char="." rowspan="1" colspan="1">0.2974</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;E<sub>0</sub></td><td align="char" char="&#xB1;" rowspan="1" colspan="1">96&#8202;&#177;&#8202;4</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">92&#8202;&#177;&#8202;5</td><td align="char" char="." rowspan="1" colspan="1">0.0072</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;E<sub>max</sub></td><td align="char" char="&#xB1;" rowspan="1" colspan="1">73&#8202;&#177;&#8202;11</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">76&#8202;&#177;&#8202;7</td><td align="char" char="." rowspan="1" colspan="1">0.4347</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#947;</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">2.9&#8202;&#177;&#8202;4.8</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">3.1&#8202;&#177;&#8202;2.0</td><td align="char" char="." rowspan="1" colspan="1">0.9776</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;EC<sub>50</sub> (&#956;g&#8202;ml<sup>&#8722;1</sup>)</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">0.10&#8202;&#177;&#8202;0.09</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">0.11&#8202;&#177;&#8202;0.09</td><td align="char" char="." rowspan="1" colspan="1">0.7761</td></tr><tr><td align="left" colspan="4" rowspan="1">95% spectral edge frequency (SEF95)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;k<sub>e0</sub> (min<sup>&#8722;1</sup>)</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">0.84&#8202;&#177;&#8202;0.36</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">0.51&#8202;&#177;&#8202;0.35</td><td align="char" char="." rowspan="1" colspan="1">0.0890</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;E<sub>0</sub></td><td align="char" char="&#xB1;" rowspan="1" colspan="1">27.0&#8202;&#177;&#8202;1.4</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">25.9&#8202;&#177;&#8202;1.8</td><td align="char" char="." rowspan="1" colspan="1">0.0724</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;E<sub>max</sub></td><td align="char" char="&#xB1;" rowspan="1" colspan="1">16.2&#8202;&#177;&#8202;1.1</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">16.8&#8202;&#177;&#8202;1.4</td><td align="char" char="." rowspan="1" colspan="1">0.2120</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#947;</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">2.3&#8202;&#177;&#8202;1.1</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">1.7&#8202;&#177;&#8202;0.5</td><td align="char" char="." rowspan="1" colspan="1">0.1964</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;EC<sub>50</sub> (&#956;g&#8202;ml<sup>&#8722;1</sup>)</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">0.09&#8202;&#177;&#8202;0.03</td><td align="char" char="&#xB1;" rowspan="1" colspan="1">0.11&#8202;&#177;&#8202;0.04</td><td align="char" char="." rowspan="1" colspan="1">0.2807</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Data are expressed as mean&#8202;&#177;&#8202;SD.</p><p>&#947;, measure of curve steepness; E<sub>0</sub>, baseline effect level; EC<sub>50</sub>, effect-site concentration producing a 50% of the maximal effect; E<sub>max</sub>, maximal effect level; k<sub>e0</sub>, elimination constant from the effect site.</p></fn></table-wrap-foot></table-wrap><p>
Figure <xref rid="F5" ref-type="fig">5</xref> shows individual relative beta ratio responses calculated from the raw EEG. The initial value before remimazolam infusion (&#8722;0.61&#8202;&#177;&#8202;0.12 at baseline versus &#8722;0.65&#8202;&#177;&#8202;0.15 during haemorrhagic shock, <italic toggle="yes">P</italic>&#8202;=&#8202;0.1376) decreased immediately after remimazolam infusion and the peak depression was observed 6&#8202;min after the initiation of remimazolam infusion (&#8722;0.96&#8202;&#177;&#8202;0.06 at baseline versus &#8722;0.97&#8202;&#177;&#8202;0.11 during haemorrhagic shock, <italic toggle="yes">P</italic>&#8202;=&#8202;0.7380). The mean changes in the relative beta ratio were similar to those for the BIS and SEF; however, in most animals, the relative beta ratio decreased again from 20 to 40&#8202;min after the start of remimazolam infusion and in some animals, the depression remained and did not return to the pre-infusion value, suggesting the relative beta ratio did not correlate with the effect-site remimazolam concentration.</p><fig position="float" id="F5" orientation="portrait"><label>Fig. 5</label><caption><p>Individual relative beta ratio changes versus time profiles at baseline and during haemorrhagic shock. The bold line in each figure represents the mean change.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ejaic-1-e007-g005.jpg"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>Our study investigated the influence of haemorrhagic shock on the pharmacokinetic and pharmacodynamic effects of remimazolam using a porcine haemorrhagic shock model. This study included animals of similar weights and ages that were bred under similar conditions, with little variation in the pharmacokinetic and pharmacodynamic profiles and EEG responses between animals. Our findings indicated that the peak remimazolam concentration increased 1.5-fold and the recovery of EEG effect was prolonged 1.5-fold during haemorrhagic shock, and were associated with a decrease in the distribution volume of central compartment, elimination clearance and fast distribution clearance. These pharmacokinetic changes did not enhance the peak EEG effect. Furthermore, the pharmacodynamic analysis indicated haemorrhagic shock did not change the end-organ sensitivity of remimazolam.</p><p>All pigs had 43% of their estimated blood volume withdrawn to induce severe haemorrhagic shock and one pig died after the completion of haemorrhage. Despite the massive haemorrhage, the impact of 1&#8202;mg&#8202;kg<sup>&#8722;1</sup> (five-fold that required for the loss of consciousness in humans<sup><xref rid="R17" ref-type="bibr">17</xref></sup>) of remimazolam on MAP was similar to that before haemorrhage (decreased by 21&#8202;&#177;&#8202;8 at baseline versus 15&#8202;&#177;&#8202;16% during haemorrhagic shock, <italic toggle="yes">P</italic>&#8202;=&#8202;0.300), and the CO was not reduced after remimazolam infusion (from 2.0&#8202;&#177;&#8202;0.5 to 2.1&#8202;&#177;&#8202;0.5&#8202;l&#8202;min<sup>&#8722;1</sup>), suggesting that remimazolam-induced cardiovascular depression was minimal, even during severe hypovolaemia.</p><p>Compared with previous haemorrhagic shock studies using pigs,<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref></sup> our pharmacokinetic analysis indicated the distribution volume was larger than remifentanil<sup><xref rid="R5" ref-type="bibr">5</xref></sup> but smaller than propofol,<sup><xref rid="R6" ref-type="bibr">6</xref></sup> and that clearance was similar to remifentanil,<sup><xref rid="R5" ref-type="bibr">5</xref></sup> suggesting the rapid onset and offset of remimazolam. Haemorrhagic shock decreased the distribution volume of the central compartment, elimination clearance and fast distribution clearance of remimazolam to 70, 63 and 48%, respectively. We speculate that the decrease in clearance was caused by a decrease in the CO (from 3.1&#8202;&#177;&#8202;0.5 to 2.0&#8202;&#177;&#8202;0.5&#8202;l&#8202;min<sup>&#8722;1</sup>), which subsequently reduced hepatic clearance. The liver is the main site of remimazolam metabolism.<sup><xref rid="R28" ref-type="bibr">28</xref></sup></p><p>On the basis of a simulation using our pharmacological findings, a reduction of the remimazolam dose to two-thirds (67%) during severe haemorrhagic shock was sufficient to obtain a potency equivalent to normal conditions. Johnson <italic toggle="yes">et al.</italic><sup><xref rid="R6" ref-type="bibr">6</xref></sup> reported that the propofol dose had to be reduced to 20% or less during severe haemorrhagic shock because of pharmacokinetic and pharmacodynamic change, and even after fluid resuscitation, it needed to be reduced to 50% because of persistent pharmacodynamic disturbance.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> Furthermore, the remifentanil dose had to be reduced to 50% because of pharmacokinetic changes.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> The requirement to reduce the dose of remimazolam might be lower than that of propofol and remifentanil after massive blood loss.</p><p>The peak EEG effect was similar between each condition despite a 1.5-fold increase in the remimazolam concentration during haemorrhagic shock. These findings might be consistent with previous reports using benzodiazepines. Miyake <italic toggle="yes">et al.</italic><sup><xref rid="R29" ref-type="bibr">29</xref></sup> reported no differences in the BIS, SEF and relative beta ratio (log ratio power 30 to 47&#8202;Hz to power 11 to 20&#8202;Hz) between patients receiving midazolam 0.2 and 0.3&#8202;mg&#8202;kg<sup>&#8722;1</sup> for the induction of general anaesthesia although plasma and effect-site concentrations were significantly higher after 0.3 than 0.2&#8202;mg&#8202;kg<sup>&#8722;1</sup>. Upton <italic toggle="yes">et al.</italic><sup><xref rid="R30" ref-type="bibr">30</xref></sup> reported that increasing the dose of remimazolam in sheep did not produce corresponding increases in maximum EEG alpha power, which can be used as a suitable measure of the sedative effects of remimazolam in sheep. Midazolam<sup><xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R32" ref-type="bibr">32</xref></sup> and remimazolam<sup><xref rid="R33" ref-type="bibr">33</xref></sup> increased the EEG activity between 13 to 30&#8202;Hz with increasing concentration, possibly resulting in a ceiling effect for the BIS and SEF, even if the effect-site concentration was increased during haemorrhagic shock.</p><p>Previous reports suggested the EEG alpha power<sup><xref rid="R30" ref-type="bibr">30</xref></sup> and relative beta ratio<sup><xref rid="R33" ref-type="bibr">33</xref></sup> are suitable for monitoring the depth of sedation during remimazolam administration. On the basis of our raw EEG analysis, the power in the alpha band in EEG showed no correlation with the effect-site remimazolam concentration. We calculated the relative beta ratio from the raw EEG (Fig. <xref rid="F5" ref-type="fig">5</xref>). The mean changes in the relative beta ratio were similar to those for the BIS and SEF, but the relative beta ratio did not correlate with the effect-site remimazolam concentration in most animals. We expect that the relative beta ratio might reflect the enhanced effect of remimazolam during haemorrhagic shock, but the peak effect did not differ between either condition, similar to the BIS and SEF. Therefore, in our study, the relative beta ratio was less suitable for evaluating the hypnotic effect of remimazolam compared with the BIS and SEF.</p><p>Our study had several limitations. First, haemorrhagic shock was not resuscitated by fluid and/or blood transfusion before remimazolam infusion. Furthermore, the influence of haemorrhagic shock on the effect of remimazolam was examined by the re-infusion of remimazolam 240&#8202;min after the first infusion at baseline conditions. We measured the plasma remimazolam concentration just before the second infusion in four animals and confirmed the blood concentration was 0.00041&#8202;&#177;&#8202;0.00035&#8202;&#956;g&#8202;ml<sup>&#8722;1</sup> (0.41&#8202;&#177;&#8202;0.35&#8202;ng&#8202;ml<sup>&#8722;1</sup>). The first infused remimazolam is probably almost eliminated, but our pharmacokinetic and pharmacodynamic findings during haemorrhagic shock might differ when remimazolam was administered as a first infusion. In addition, as mentioned above, we used the BIS and SEF to evaluate the pharmacodynamic effect of remimazolam because the alpha power and relative beta ratio were not superior to BIS and SEF in the present study. However, it was unclear whether the BIS and SEF were appropriate for evaluating the pharmacodynamic effect of remimazolam, and of note, the BIS has no reliable validation in the swine study. Finally, the study used a small convenience sample, and our results may only be considered as exploratory. Further clinical studies are required to validate our findings.</p><p>In conclusion, haemorrhagic shock increased remimazolam concentration, and was associated with pharmacokinetic changes, but it did not change the end-organ sensitivity. Our findings indicate that the impact of haemorrhagic shock on the pharmacological effect of remimazolam is small, and that remimazolam might be a more suitable sedative/hypnotic than propofol and midazolam for the management of patients who have massive bleeding.</p></sec></body><back><ack><title>Acknowledgements relating to this article</title><p>Assistance with the study: we thank J. Ludovic Croxford, PhD, from Edanz for editing a draft of this manuscript.</p><p>Financial support and sponsorship: none.</p><p content-type="COI-statement">Conflicts of interest: none.</p><p>Presentation: none.</p><p>This manuscript was handled by Michelle Chew.</p></ack><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiskopf</surname><given-names>RB</given-names></name><name name-style="western"><surname>Bogertz</surname><given-names>MS</given-names></name></person-group>. <article-title>Haemorrhage decreases the anaesthetic requirement for ketamine and thiopentone in the pig</article-title>. <source><italic toggle="yes">Br J Anaesth</italic></source><year>1985</year>; <volume>57</volume>:<fpage>1022</fpage>&#8211;<lpage>1025</lpage>.<pub-id pub-id-type="pmid">4041308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bja/57.10.1022</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Paepe</surname><given-names>P</given-names></name><name name-style="western"><surname>Belpaire</surname><given-names>FM</given-names></name><name name-style="western"><surname>Rosseel</surname><given-names>MT</given-names></name><name name-style="western"><surname>Buylaert</surname><given-names>WA</given-names></name></person-group>. <article-title>The influence of hemorrhagic shock on the pharmacokinetics and the analgesic effect of morphine in the rat</article-title>. <source><italic toggle="yes">Fundam Clin Pharmacol</italic></source><year>1998</year>; <volume>12</volume>:<fpage>624</fpage>&#8211;<lpage>630</lpage>.<pub-id pub-id-type="pmid">9818295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1472-8206.1998.tb00996.x</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Paepe</surname><given-names>P</given-names></name><name name-style="western"><surname>Belpaire</surname><given-names>FM</given-names></name><name name-style="western"><surname>Van Hoey</surname><given-names>G</given-names></name><etal/></person-group><article-title>Influence of hypovolemia on the pharmacokinetics and the electroencephalographic effect of etomidate in the rat</article-title>. <source><italic toggle="yes">J Pharmacol Exp Ther</italic></source><year>1999</year>; <volume>290</volume>:<fpage>1048</fpage>&#8211;<lpage>1053</lpage>.<pub-id pub-id-type="pmid">10454477</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Paepe</surname><given-names>P</given-names></name><name name-style="western"><surname>Belpaire</surname><given-names>FM</given-names></name><name name-style="western"><surname>Rosseel</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Influence of hypovolemia on the pharmacokinetics and the electroencephalographic effect of propofol in the rat</article-title>. <source><italic toggle="yes">Anesthesiology</italic></source><year>2000</year>; <volume>93</volume>:<fpage>1482</fpage>&#8211;<lpage>1490</lpage>.<pub-id pub-id-type="pmid">11149444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-200012000-00021</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>KB</given-names></name><name name-style="western"><surname>Kern</surname><given-names>SE</given-names></name><name name-style="western"><surname>Hamber</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Influence of hemorrhagic shock on remifentanil: a pharmacokinetic and pharmacodynamic analysis</article-title>. <source><italic toggle="yes">Anesthesiology</italic></source><year>2001</year>; <volume>94</volume>:<fpage>322</fpage>&#8211;<lpage>332</lpage>.<pub-id pub-id-type="pmid">11176098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-200102000-00023</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>KB</given-names></name><name name-style="western"><surname>Egan</surname><given-names>TD</given-names></name><name name-style="western"><surname>Kern</surname><given-names>SE</given-names></name><etal/></person-group><article-title>The influence of hemorrhagic shock on propofol: a pharmacokinetic and pharmacodynamic analysis</article-title>. <source><italic toggle="yes">Anesthesiology</italic></source><year>2003</year>; <volume>99</volume>:<fpage>409</fpage>&#8211;<lpage>420</lpage>.<pub-id pub-id-type="pmid">12883414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-200308000-00023</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shafer</surname><given-names>SL</given-names></name></person-group>. <article-title>Shock values</article-title>. <source><italic toggle="yes">Anesthesiology</italic></source><year>2004</year>; <volume>101</volume>:<fpage>567</fpage>&#8211;<lpage>568</lpage>.<pub-id pub-id-type="pmid">15329579</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-200409000-00002</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egan</surname><given-names>TD</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>KB</given-names></name></person-group>. <article-title>The influence of hemorrhagic shock on the disposition and effects of intravenous anesthetics: a narrative review</article-title>. <source><italic toggle="yes">Anesth Analg</italic></source><year>2020</year>; <volume>130</volume>:<fpage>1320</fpage>&#8211;<lpage>1330</lpage>.<pub-id pub-id-type="pmid">32149755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0000000000004654</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>KB</given-names></name><name name-style="western"><surname>Egan</surname><given-names>TD</given-names></name><name name-style="western"><surname>Kern</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Influence of hemorrhagic shock followed by crystalloid resuscitation on propofol: a pharmacokinetic and pharmacodynamic analysis</article-title>. <source><italic toggle="yes">Anesthesiology</italic></source><year>2004</year>; <volume>101</volume>:<fpage>647</fpage>&#8211;<lpage>659</lpage>.<pub-id pub-id-type="pmid">15329589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-200409000-00013</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takizawa</surname><given-names>E</given-names></name><name name-style="western"><surname>Takizawa</surname><given-names>D</given-names></name><name name-style="western"><surname>Hiraoka</surname><given-names>H</given-names></name><etal/></person-group><article-title>Disposition and pharmacodynamics of propofol during isovolaemic haemorrhage followed by crystalloid resuscitation in humans</article-title>. <source><italic toggle="yes">Br J Clin Pharmacol</italic></source><year>2006</year>; <volume>61</volume>:<fpage>256</fpage>&#8211;<lpage>261</lpage>.<pub-id pub-id-type="pmid">16487218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2005.02555.x</pub-id><pub-id pub-id-type="pmcid">PMC1885011</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masui</surname><given-names>K</given-names></name></person-group>. <article-title>Remimazolam besilate, a benzodiazepine, has been approved for general anesthesia!!</article-title>. <source><italic toggle="yes">J Aneth</italic></source><year>2020</year>; <volume>34</volume>:<fpage>479</fpage>&#8211;<lpage>482</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00540-020-02755-1</pub-id><pub-id pub-id-type="pmid">32157465</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kilpatrick</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Mclntyre</surname><given-names>MS</given-names></name><name name-style="western"><surname>Cox</surname><given-names>RF</given-names></name><etal/></person-group><article-title>CNS 7056: a novel ultra-short-acting benzodiazepine</article-title>. <source><italic toggle="yes">Anesthesiology</italic></source><year>2007</year>; <volume>107</volume>:<fpage>60</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="pmid">17585216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.anes.0000267503.85085.c0</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Remmel</surname><given-names>RP</given-names></name><name name-style="western"><surname>Mann</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Beilman</surname><given-names>GJ</given-names></name></person-group>. <article-title>Drug metabolism in hemorrhagic shock: pharmacokinetics of selective markers of cytochrome-P450 2C9, 2D6, and 3A4 enzyme activities in a porcine model</article-title>. <source><italic toggle="yes">J Surg Res</italic></source><year>2011</year>; <volume>167</volume>:<fpage>e231</fpage>&#8211;<lpage>e243</lpage>.<pub-id pub-id-type="pmid">20850770</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jss.2010.06.040</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furuta</surname><given-names>M</given-names></name><name name-style="western"><surname>Ito</surname><given-names>H</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>M</given-names></name></person-group>. <article-title>Anaesthetic management using remimazolam in a patient with severe aortic stenosis: a case report</article-title>. <source><italic toggle="yes">BMC Anesthesiol</italic></source><year>2021</year>; <volume>21</volume>:<fpage>202</fpage>.<pub-id pub-id-type="pmid">34391395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12871-021-01422-6</pub-id><pub-id pub-id-type="pmcid">PMC8364063</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Lai</surname><given-names>T</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effect of remimazolam induction on hemodynamics in patients undergoing valve replacement surgery: a randomized, double-blind, controlled trial</article-title>. <source><italic toggle="yes">Pharmacol Res Perspect</italic></source><year>2021</year>; <volume>9</volume>:<fpage>e00851</fpage>.<pub-id pub-id-type="pmid">34390228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/prp2.851</pub-id><pub-id pub-id-type="pmcid">PMC8363771</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>K</given-names></name><name name-style="western"><surname>Ohno</surname><given-names>S</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>M</given-names></name><etal/></person-group><article-title>Remimazolam anesthesia for cardiac surgery with cardiopulmonary bypass: a case report</article-title>. <source><italic toggle="yes">JA Clin Rep</italic></source><year>2021</year>; <volume>7</volume>:<fpage>21</fpage>.<pub-id pub-id-type="pmid">33677710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40981-021-00424-0</pub-id><pub-id pub-id-type="pmcid">PMC7937000</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doi</surname><given-names>M</given-names></name><name name-style="western"><surname>Hirata</surname><given-names>N</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name><etal/></person-group><article-title>Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III): results of a multicenter, randomized, double-blind, parallel-group comparative trial</article-title>. <source><italic toggle="yes">J Anesth</italic></source><year>2020</year>; <volume>34</volume>:<fpage>491</fpage>&#8211;<lpage>501</lpage>.<pub-id pub-id-type="pmid">32303884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00540-020-02776-w</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurita</surname><given-names>T</given-names></name><name name-style="western"><surname>Takata</surname><given-names>K</given-names></name><name name-style="western"><surname>Uraoka</surname><given-names>M</given-names></name><etal/></person-group><article-title>The influence of hemorrhagic shock on the minimum alveolar anesthetic concentration of isoflurane in a swine model</article-title>. <source><italic toggle="yes">Anesth Analg</italic></source><year>2007</year>; <volume>105</volume>:<fpage>1639</fpage>&#8211;<lpage>1643</lpage>.<pub-id pub-id-type="pmid">18042861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/01.ane.0000287252.39383.17</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imoto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mino</surname><given-names>Y</given-names></name><name name-style="western"><surname>Naito</surname><given-names>T</given-names></name><etal/></person-group><article-title>Simultaneous determination of itraconazole and its CYP3A4-mediated metabolites including N-desalkyl itraconazole in human plasma using liquid chromatography-tandem mass spectrometry and its clinical application</article-title>. <source><italic toggle="yes">J Pharm Healthcare Sci</italic></source><year>2020</year>; <volume>6</volume>:<fpage>11</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40780-020-00167-7</pub-id><pub-id pub-id-type="pmcid">PMC7199303</pub-id><pub-id pub-id-type="pmid">32391164</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurita</surname><given-names>T</given-names></name><name name-style="western"><surname>Takata</surname><given-names>K</given-names></name><name name-style="western"><surname>Morita</surname><given-names>K</given-names></name><etal/></person-group><article-title>The influence of hemorrhagic shock on the electroencephalographic and immobilizing effects of propofol in a swine model</article-title>. <source><italic toggle="yes">Anesth Analg</italic></source><year>2009</year>; <volume>109</volume>:<fpage>398</fpage>&#8211;<lpage>404</lpage>.<pub-id pub-id-type="pmid">19608809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ane.0b013e3181a96f9a</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurita</surname><given-names>T</given-names></name><name name-style="western"><surname>Morita</surname><given-names>K</given-names></name><name name-style="western"><surname>Fukuda</surname><given-names>K</given-names></name><etal/></person-group><article-title>Influence of hypovolemia on the electroencephalographic effect of isoflurane in a swine model</article-title>. <source><italic toggle="yes">Anesthesiology</italic></source><year>2005</year>; <volume>102</volume>:<fpage>948</fpage>&#8211;<lpage>953</lpage>.<pub-id pub-id-type="pmid">15851881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-200505000-00013</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurita</surname><given-names>T</given-names></name><name name-style="western"><surname>Morita</surname><given-names>K</given-names></name><name name-style="western"><surname>Fukuda</surname><given-names>K</given-names></name><etal/></person-group><article-title>Influence of hemorrhagic shock and subsequent fluid resuscitation on the electroencephalographic effect of isoflurane in a swine model</article-title>. <source><italic toggle="yes">Anesthesiology</italic></source><year>2005</year>; <volume>103</volume>:<fpage>1189</fpage>&#8211;<lpage>1194</lpage>.<pub-id pub-id-type="pmid">16306731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-200512000-00013</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurita</surname><given-names>T</given-names></name><name name-style="western"><surname>Morita</surname><given-names>K</given-names></name><name name-style="western"><surname>Fukuda</surname><given-names>K</given-names></name><etal/></person-group><article-title>Landiolol, an ultra-short-acting beta 1-adrenoceptor antagonist, does not alter the electroencephalographic effect of isoflurane in swine model</article-title>. <source><italic toggle="yes">Br J Anaesth</italic></source><year>2006</year>; <volume>96</volume>:<fpage>602</fpage>&#8211;<lpage>607</lpage>.<pub-id pub-id-type="pmid">16567345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bja/ael069</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurita</surname><given-names>T</given-names></name><name name-style="western"><surname>Takata</surname><given-names>K</given-names></name><name name-style="western"><surname>Morita</surname><given-names>K</given-names></name><name name-style="western"><surname>Sato</surname><given-names>S</given-names></name></person-group>. <article-title>Lipophilic beta-adrenoceptor antagonist propranolol increases the hypnotic and antinociceptive effects of isoflurane in a swine model</article-title>. <source><italic toggle="yes">Br J Anaesth</italic></source><year>2008</year>; <volume>100</volume>:<fpage>841</fpage>&#8211;<lpage>845</lpage>.<pub-id pub-id-type="pmid">18424803</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bja/aen089</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurita</surname><given-names>T</given-names></name><name name-style="western"><surname>Takata</surname><given-names>K</given-names></name><name name-style="western"><surname>Morita</surname><given-names>K</given-names></name><etal/></person-group><article-title>The influence of endotoxemia on the electroencephalographic and antinociceptive effects of isoflurane in a swine model</article-title>. <source><italic toggle="yes">Anesth Analg</italic></source><year>2010</year>; <volume>110</volume>:<fpage>83</fpage>&#8211;<lpage>88</lpage>.<pub-id pub-id-type="pmid">19897800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0b013e3181c22146</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurita</surname><given-names>T</given-names></name><name name-style="western"><surname>Kawashima</surname><given-names>S</given-names></name><name name-style="western"><surname>Morita</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>Y</given-names></name></person-group>. <article-title>Intracranial space-occupying lesion inducing intracranial hypertension increases the encephalographic effects of isoflurane in a swine model</article-title>. <source><italic toggle="yes">J Neurosurg Anesthesiol</italic></source><year>2019</year>; <volume>31</volume>:<fpage>70</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">29683966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ANA.0000000000000503</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>AV</given-names></name></person-group>. <article-title>The possible effect of the aggregation of the molecules of hemoglobin on its dissociation curves</article-title>. <source><italic toggle="yes">J Physiol</italic></source><year>1910</year>; <volume>40</volume>:<fpage>4</fpage>&#8211;<lpage>7</lpage>.</mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>St&#246;hr</surname><given-names>T</given-names></name><name name-style="western"><surname>Colin</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Ossig</surname><given-names>J</given-names></name><etal/></person-group><article-title>Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment</article-title>. <source><italic toggle="yes">Br J Anaesth</italic></source><year>2021</year>; <volume>127</volume>:<fpage>415</fpage>&#8211;<lpage>423</lpage>.<pub-id pub-id-type="pmid">34246461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bja.2021.05.027</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyake</surname><given-names>W</given-names></name><name name-style="western"><surname>Oda</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Electroencephalographic response following midazolam-induced general anesthesia: relationship to plasma and effect-site midazolam concentrations</article-title>. <source><italic toggle="yes">J Anesth</italic></source><year>2010</year>; <volume>24</volume>:<fpage>386</fpage>&#8211;<lpage>393</lpage>.<pub-id pub-id-type="pmid">20229000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00540-010-0907-4</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Upton</surname><given-names>RN</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>AM</given-names></name><name name-style="western"><surname>Grant</surname><given-names>C</given-names></name></person-group>. <article-title>A dose escalation study in sheep of the effects of the benzodiazepine CNS 7056 on sedation, the EEG and the respiratory and cardiovascular systems</article-title>. <source><italic toggle="yes">Br J Pharmacol</italic></source><year>2008</year>; <volume>155</volume>:<fpage>52</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">18552878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjp.2008.228</pub-id><pub-id pub-id-type="pmcid">PMC2527850</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veselis</surname><given-names>RA</given-names></name><name name-style="western"><surname>Reinsel</surname><given-names>R</given-names></name><name name-style="western"><surname>Alagesan</surname><given-names>R</given-names></name><etal/></person-group><article-title>The EEG as a monitor of midazolam amnesia: changes in power and topography as a function of amnesic state</article-title>. <source><italic toggle="yes">Anesthesiology</italic></source><year>1991</year>; <volume>74</volume>:<fpage>866</fpage>&#8211;<lpage>874</lpage>.<pub-id pub-id-type="pmid">2021203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-199105000-00011</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenblatt</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Ehrenberg</surname><given-names>BL</given-names></name><name name-style="western"><surname>Culm</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Kinetics and EEG effects of midazolam during and after 1-min, 1-h, and 3-h intravenous infusions</article-title>. <source><italic toggle="yes">J Clin Pharmacol</italic></source><year>2004</year>; <volume>44</volume>:<fpage>605</fpage>&#8211;<lpage>611</lpage>.<pub-id pub-id-type="pmid">15145968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0091270004265368</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eisenried</surname><given-names>A</given-names></name><name name-style="western"><surname>Sch&#252;ttler</surname><given-names>J</given-names></name><name name-style="western"><surname>Lerch</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers</article-title>. <source><italic toggle="yes">Anesthesiology</italic></source><year>2020</year>; <volume>132</volume>:<fpage>652</fpage>&#8211;<lpage>666</lpage>.<pub-id pub-id-type="pmid">31972657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0000000000003102</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>